Leveraging Smart Engineering for Sophisticated Bi- & Multispecific Molecular Design with Improved Specificity, Expanded Therapeutic Windows & Optimized Developability to Achieve Clinical Validation & Derisk CMC
The bispecific, multispecific and cell engager space is entering a new era of clinical validation and rapid innovation, as next-generation formats and sophisticated molecular architectures move closer to patients. Following a year marked by landmark clinical readouts for BiTEs and major acquisitions in the VEGF/PD1 space, 2026 will define the next wave of differentiated bispecifics across oncology, immunology and beyond.
The 17th World Bispecific Summit US returns as the definitive forum for navigating this complexity, bringing together leaders in antibody discovery, protein engineering, translational science and early clinical development to accelerate highly innovative multi-target therapeutics with optimized specificity, developability and therapeutic windows.
Unlike broader antibody or protein engineering meetings, this highly focused community connects the full drug development value chain, from early discovery through to preclinical and clinical development, ensuring discussions are practical, technical and directly relevant to pipeline progression.
As competitive pressure intensifies and biologics lose exclusivity, there has never been a more critical moment to refine your strategy, validate next-gen formats, and position your bispecific, multispecific and cell engager programs for clinical success. Join the experts shaping the future of bispecifics from the likes of AstraZeneca, Pfizer, Merck, Amgen and more as this drug modality demonstrates superior specificity, safety, efficacy and differentiation, and caters to patients with unmet need.
-
The World Bispecific Summit is an ideal forum to hear from cutting edge experts, connect with stakeholders spanning molecule design to translation, and explore the next sets of challenges facing the field.
Jay Fine, President, Research & Development, EvolveImmune Therapeutics
-
The meeting offers direct exposure to industry leaders and KOLs from pharma and biotech. Attend if you want a practical, scientifically dense meeting on how to design, de-risk and clinically validate next generation bi/multi-specific therapeutics.
Agnish Dey, Senior Scientist, Takeda Pharmaceuticals
-
This conference provides the opportunity to see cutting edge developments in the field of bispecific antibodies. The intimate nature of the conference facilitates connections and ad hoc conversations with peers that can be difficult to find at larger events.
Jared Shadish, Senior Scientist, AstraZeneca
Explore the Full World Bispecific Summit Agenda
- Get a full overview of the bispecific agenda, expert speaker faculty, and deep-dive seminar day
- Preview cutting-edge case studies spanning co-stimulation, masking and conditional activation approaches to complex formats
- Explore exclusive content including panels on industry trends, innovation showcases, and practical insights into next-generation bispecific design
- Easily share with colleagues and decision-makers evaluating partners, platforms, and strategies in the bispecific space
2025 Speakers
Official Partners
Attending Companies Include
Explore Related Events
Discover the 2026 Agenda
Catch the latest industry breakthroughs, emerging trends and exclusive insights by participating in our dynamic roundtables and panel discussions.
Partner With Us
As the field rapidly expands and matures, position yourself alongside leading solution providers to ensure your brand stands out as a premier choice amid growing competition.
Join Your Community
Immerse yourself in critical conversations with like-minded experts spanning all stages of R&D from target biology, antibody discovery and engineering to developability assessment and clinical development of bispecifics and build invaluable connections.